What is CJC-1295 DAC?
CJC-1295 DAC is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) modification binds reversibly to albumin, extending the peptide’s half-life to approximately 6–8 days. By stimulating pituitary GHRH receptors, CJC-1295 DAC increases GH secretion and circulating IGF-1 in a dose-dependent manner.
Research classification: Research summary · not a validated human regimen. The CJC-1295 DAC 5 mg vial label reports nominal content; it does not state a suitable amount for human use.
Mechanism and research questions
Supports sustained elevation of GH and IGF-1. May promote increased lean body mass, reduced fat mass, and improved body composition. Enhanced protein synthesis and recovery potential.
Mechanistic findings and early experiments do not by themselves establish clinical efficacy, an approved treatment cycle or equivalence between suppliers' formulations. Interpret claims in the context of the specific experimental model and references.
How to read a reported schedule
The earlier catalogue entry described research examples, not a clinically validated schedule for people. The dose, route, frequency or escalation used in one experiment cannot be generalised to a different formulation or to an individual. When primary evidence is not available, do not treat a catalogue number as a recommendation.
For the existing schedule, its evidence caveats and the concentration calculator, see the CJC-1295 DAC protocol and vial reference. Figures displayed there are research context, not a personalised prescription.
Vial identity and preparation
No verified Peak Peptides image matches this exact compound and 5 mg vial. We leave the image blank rather than implying another product is the same.
Reconstitution cannot be inferred from vial strength alone. Confirm the exact compound, lot, expected appearance, compatible sterile diluent, final volume, transfer method and discard/storage period from validated formulation documentation. BAC water and a 28-day period are not universal defaults. See the illustrated product-specific preparation guide and the abnormal-solution safety guide.
Sources, limits and next steps
No independently reviewed primary human protocol has been attached to this catalogue article. A cited bibliography should be obtained before interpreting any reported schedule.
For clinical decisions, consult a qualified professional and the product information for an approved formulation. Research-only supplier material must not be injected or used to treat a condition. Explore the A–Z research directory to compare evidence categories.